{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:58:04Z","timestamp":1792267084086,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T00:00:00Z","timestamp":1318291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s11060-011-0722-2","type":"journal-article","created":{"date-parts":[[2011,10,10]],"date-time":"2011-10-10T16:07:34Z","timestamp":1318262854000},"page":"155-164","source":"Crossref","is-referenced-by-count":117,"title":["Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab na\u00efve, recurrent glioblastoma"],"prefix":"10.1007","volume":"107","author":[{"given":"David A.","family":"Reardon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridharan","family":"Gururangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger E.","family":"McLendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"James E.","family":"Herndon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Bulusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevie","family":"Threatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Vredenburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry S.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,11]]},"reference":[{"key":"722_CR1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131\u20131138","journal-title":"Oncologist"},{"key":"722_CR2","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1200\/JCO.2009.26.9027","volume":"28","author":"W Wick","year":"2010","unstructured":"Wick W, Weller M, van den Bent M, Stupp R (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 28:e188\u2013e189. doi:\n                    10.1200\/JCO.2009.26.9027\n                    \n                   author reply e190\u2013182","journal-title":"J Clin Oncol"},{"key":"722_CR3","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740","journal-title":"J Clin Oncol"},{"key":"722_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740\u2013745","journal-title":"J Clin Oncol"},{"key":"722_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1215\/S1152851703000620","volume":"6","author":"KR Lamborn","year":"2004","unstructured":"Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncol 6:227\u2013235","journal-title":"Neuro-oncol"},{"key":"722_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1215\/15228517-2006-025","volume":"9","author":"KV Ballman","year":"2007","unstructured":"Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-oncology 9:29\u201338","journal-title":"Neuro-oncology"},{"key":"722_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/neuonc\/nop019","volume":"12","author":"W Wu","year":"2010","unstructured":"Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O\u2019Fallon JR, Jaeckle KA, Prados MD (2010) Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-oncology 12:164\u2013172. doi:\n                    10.1093\/neuonc\/nop019","journal-title":"Neuro-oncology"},{"key":"722_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/359845a0","volume":"359","author":"KH Plate","year":"1992","unstructured":"Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845\u2013848","journal-title":"Nature"},{"key":"722_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/367576a0","volume":"367","author":"B Millauer","year":"1994","unstructured":"Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576\u2013579","journal-title":"Nature"},{"key":"722_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249\u2013257","journal-title":"Nature"},{"key":"722_CR11","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"HF Dvorak","year":"2002","unstructured":"Dvorak HF (2002) Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368\u20134380","journal-title":"J Clin Oncol"},{"key":"722_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58\u201362","journal-title":"Science"},{"key":"722_CR13","first-page":"553","volume":"6","author":"F Winkler","year":"2004","unstructured":"Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553\u2013563","journal-title":"Cancer Cell"},{"key":"722_CR14","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","volume":"64","author":"RT Tong","year":"2004","unstructured":"Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731\u20133736","journal-title":"Cancer Res"},{"key":"722_CR15","first-page":"5565","volume":"60","author":"CG Lee","year":"2000","unstructured":"Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y (2000) Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565\u20135570","journal-title":"Cancer Res"},{"key":"722_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","volume":"165","author":"T Inai","year":"2004","unstructured":"Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35\u201352","journal-title":"Am J Pathol"},{"key":"722_CR17","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/sj.bjc.6601005","volume":"88","author":"H Wildiers","year":"2003","unstructured":"Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88:1979\u20131986","journal-title":"Br J Cancer"},{"key":"722_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145\u2013147","journal-title":"Nat Med"},{"key":"722_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","volume":"11","author":"TT Batchelor","year":"2007","unstructured":"Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83\u201395","journal-title":"Cancer Cell"},{"key":"722_CR20","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963\u20131972","journal-title":"J Clin Oncol"},{"key":"722_CR21","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722\u20134729","journal-title":"J Clin Oncol"},{"key":"722_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2307\/2530298","volume":"38","author":"SJ Pocock","year":"1982","unstructured":"Pocock SJ (1982) Interim analyses for randomized clinical trials: the group sequential approach. Biometrics 38:153\u2013162","journal-title":"Biometrics"},{"key":"722_CR23","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","volume":"13","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253\u20131259","journal-title":"Clin Cancer Res"},{"key":"722_CR24","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1002\/cncr.25462","volume":"116","author":"JJ Raizer","year":"2010","unstructured":"Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J, Bredel M (2010) A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116:5297\u20135305. doi:\n                    10.1002\/cncr.25462","journal-title":"Cancer"},{"key":"722_CR25","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/sj.bjc.6605412","volume":"101","author":"DA Reardon","year":"2009","unstructured":"Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE 2nd, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS (2009) Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101:1986\u20131994","journal-title":"Br J Cancer"},{"key":"722_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/neuonc\/nop063","volume":"12","author":"B Hasselbalch","year":"2010","unstructured":"Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sorensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS (2010) Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 12:508\u2013516. doi:\n                    10.1093\/neuonc\/nop063","journal-title":"Neuro-oncology"},{"key":"722_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijrobp.2008.10.043","volume":"75","author":"PH Gutin","year":"2009","unstructured":"Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156\u2013163","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"722_CR28","doi-asserted-by":"publisher","unstructured":"Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE, 2nd, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ (2011) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. doi:\n                    10.1002\/cncr.26381","DOI":"10.1002\/cncr.26381"},{"key":"722_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427\u2013434","journal-title":"N Engl J Med"},{"key":"722_CR30","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"722_CR31","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666\u20132676","journal-title":"N Engl J Med"},{"key":"722_CR32","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"722_CR33","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","volume":"17","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516\u20131525","journal-title":"J Clin Oncol"},{"key":"722_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/00000421-199612000-00016","volume":"19","author":"MD Prados","year":"1996","unstructured":"Prados MD, Warnick RE, Mack EE, Chandler KL, Rabbitt J, Page M, Malec M (1996) Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial. Am J Clin Oncol 19:609\u2013612","journal-title":"Am J Clin Oncol"},{"key":"722_CR35","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.1991.9.5.860","volume":"9","author":"WK Yung","year":"1991","unstructured":"Yung WK, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9:860\u2013864","journal-title":"J Clin Oncol"},{"key":"722_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1215\/S1152851703000218","volume":"6","author":"TT Batchelor","year":"2004","unstructured":"Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S (2004) Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97\u201311. Neuro-oncol 6:21\u201327","journal-title":"Neuro-oncol"},{"key":"722_CR37","first-page":"2940","volume":"9","author":"MR Gilbert","year":"2003","unstructured":"Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S (2003) Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9:2940\u20132949","journal-title":"Clin Cancer Res"},{"issue":"2","key":"722_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11060-008-9749-4","volume":"92","author":"M Santisteban","year":"2009","unstructured":"Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E (2009) Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: north central cancer treatment group results. J Neurooncol 92(2):165\u2013175","journal-title":"J Neurooncol"},{"key":"722_CR39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s002800050771","volume":"41","author":"CA Coggins","year":"1998","unstructured":"Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, Friedman HS (1998) Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 41:485\u2013490","journal-title":"Cancer Chemother Pharmacol"},{"key":"722_CR40","first-page":"4154","volume":"6","author":"VJ Patel","year":"2000","unstructured":"Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, Dolan ME, Bigner DD, Friedman HS (2000) Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res 6:4154\u20134157","journal-title":"Clin Cancer Res"},{"key":"722_CR41","first-page":"4110","volume":"6","author":"PJ Houghton","year":"2000","unstructured":"Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA, Tan M, Friedman HS, Brent TP (2000) Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6:4110\u20134118","journal-title":"Clin Cancer Res"},{"key":"722_CR42","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s002800050050","volume":"45","author":"RC Castellino","year":"2000","unstructured":"Castellino RC, Elion GB, Keir ST, Houghton PJ, Johnson SP, Bigner DD, Friedman HS (2000) Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother Pharmacol 45:345\u2013349","journal-title":"Cancer Chemother Pharmacol"},{"key":"722_CR43","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1158\/0008-5472.CAN-06-4102","volume":"67","author":"RK Jain","year":"2007","unstructured":"Jain RK, Tong RT, Munn LL (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67:2729\u20132735","journal-title":"Cancer Res"},{"key":"722_CR44","doi-asserted-by":"crossref","unstructured":"Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon I, J. E., Coan A, Threatt S, Friedman AH, Friedman HS (2011) Phase II study of carboplatin, irinotecan and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer (in press)","DOI":"10.1007\/s11060-011-0722-2"},{"key":"722_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1535-7163.MCT-07-0552","volume":"7","author":"A Claes","year":"2008","unstructured":"Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP (2008) Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 7:71\u201378. doi:\n                    10.1158\/1535-7163.MCT-07-0552","journal-title":"Mol Cancer Ther"},{"key":"722_CR46","first-page":"169","volume":"88","author":"K Lamszus","year":"2003","unstructured":"Lamszus K, Kunkel P, Westphal M (2003) Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 88:169\u2013177","journal-title":"Acta Neurochir Suppl"},{"key":"722_CR47","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/sj.neo.7900102","volume":"2","author":"JL Rubenstein","year":"2000","unstructured":"Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306\u2013314","journal-title":"Neoplasia"},{"key":"722_CR48","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232\u2013239","journal-title":"Cancer Cell"},{"key":"722_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220\u2013231","journal-title":"Cancer Cell"},{"key":"722_CR50","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/neuonc\/nop027","volume":"12","author":"JF Groot de","year":"2010","unstructured":"de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology 12:233\u2013242. doi:\n                    10.1093\/neuonc\/nop027","journal-title":"Neuro-oncology"},{"key":"722_CR51","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1212\/WNL.0b013e3181bc0184","volume":"73","author":"FM Iwamoto","year":"2009","unstructured":"Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200\u20131206","journal-title":"Neurology"},{"key":"722_CR52","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1073\/pnas.1014480108","volume":"108","author":"O Keunen","year":"2011","unstructured":"Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 108:3749\u20133754. doi:\n                    10.1073\/pnas.1014480108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"722_CR53","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280","journal-title":"J Clin Oncol"},{"issue":"12","key":"722_CR54","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/neuonc\/noq099","volume":"12","author":"S Sathornsumetee","year":"2010","unstructured":"Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA (2010) Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12(12):1300\u20131310","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0722-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-011-0722-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0722-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0722-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T21:14:46Z","timestamp":1581974086000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-011-0722-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,11]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s11060-011-0722-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,11]]}}}